- Conditions
- Acute DVT of Lower Extremity
- Interventions
- Vascular Boot, Standard of Care
- Combination Product · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 201
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Venous Thromboembolism, Brain Tumors
- Interventions
- Not listed
- Lead sponsor
- Ontario Clinical Oncology Group (OCOG)
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Salt Lake City, Utah
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
- Interventions
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,868 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
- Conditions
- Brain Injury, Venous Thrombosis
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- enoxaparin, heparin
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1999
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
- Interventions
- Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Danaparoid Sodium, Argatroban
- Drug
- Lead sponsor
- Aspen Global Incorporated
- Industry
- Eligibility
- 2 Weeks to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more
- Conditions
- Antithrombotic
- Interventions
- Enoxaparin, unfractionated heparin (UFH), BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Cancer Patients First-ever Acute Ischemic Stroke
- Interventions
- Enoxaparin, Aspirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 8,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
- Conditions
- Thrombosis, Hip Replacement
- Interventions
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • Sarasota, Florida • Austin, Texas
- Conditions
- Venous Thromboembolism
- Interventions
- dalteparin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- Venous Thromboembolism, Pulmonary Embolism
- Interventions
- VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Venous Thromboembolism, Thromboprophylaxis, Trauma
- Interventions
- Aspirin, Enoxaparin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Thromboembolism
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Patients Receiving Rivaroxaban Treatment
- Interventions
- STA- Rivaroxaban Calibrator&Control
- Device
- Lead sponsor
- Diagnostica Stago
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
- Conditions
- Venous Thrombosis
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
- Conditions
- Kidney Cancer
- Interventions
- tinzaparin sodium
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Lebanon, New Hampshire • Burlington, Vermont
- Conditions
- Pancreatic Cancer
- Interventions
- Docetaxel, Liposomal Doxorubicin, Enoxaparin
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pancreatic Cancer, Venous Thromboembolism
- Interventions
- Dalteparin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Venous Thromboembolism
- Interventions
- Semuloparin sodium, Enoxaparin sodium, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban, Enoxaparin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
- Conditions
- Thromboembolism, Venous
- Interventions
- enoxaparin
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas